Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2023: Featuring Iovance, Candel Therapeutics & Replimune – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non-Small Cell Lung Cancer (NSCLC) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for Non-Small Cell Lung Cancer (NSCLC).

In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional 7 geographical markets (7M), totaling 15 major markets (15MM). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the publisher’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of NSCLC, with pricing assumptions based on currently marketed products by class of cell & gene therapies, accompanied by a transparent forecast methodology.

Additionally, the report evaluates indication-specific unmet needs and competitive assessment, and identifies key future players in the cell therapy market.

• Cell & gene therapies (CGTs) constitute a very small proportion of the overall NSCLC pipeline and will face a high level of competition. Cell therapies, consisting mostly of tumor-infiltrating lymphocytes (TILs) and CAR-T cells, are the most-abundant modality type in the NSCLC CGT pipeline but fall far behind traditional therapies such as monoclonal antibodies and small molecules.
• Tumor-infiltrating lymphocytes and gene therapies are the most promising CGT classes for treating NSCLC. TILs are among the few CGT technologies that have demonstrated clinical activity in NSCLC, including even complete responses (CR).
• The publisher’s patient-based forecast projects the NSCLC cell therapy market across the 8MM to reach $2.8 billion in 2031, while across the 15M, the overall NSCLC market sales are projected to reach peak sales of $45.4 billion. Using a drug-level forecast approach, cell therapies are expected to reach $1.2 billion in peak sales in eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China), followed by gene therapies with $920 million.
• A low level of unmet need for CGT agents exists in most NSCLC patient populations, with exceptions that can prove very lucrative. NSCLC presents with niche unmet needs across specific patient populations, which makes an indication-wide impact by CGT therapies unlikely. However, CGT does have an increased potential to address some of the current unmet needs in the settings of resistance to immunotherapy, as well as personalized approaches to tackle resistance to any therapies.

Scope

This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

• Obtain cell & gene therapy sales forecasts across multiple regions
• Gain insight into promising early stage approaches

Our indication specific forecast models answer questions such as:

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?

   

   

Key Topics Covered:

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. Etiology, Epidemiology & Treatment Algorithm

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

5.2. 10-Year Market Outlook Across the 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

9. Future Players and Catalyst

10. Appendix

10.1. Cell & Gene Therapies Forecast Methodology Overview

10.2. Pricing of Cell & Gene Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations and Definitions

10.5. Methodology

10.6. About the Authors

11. Contact the Publisher

A selection of companies mentioned in this report includes

• Iovance
• Candel Therapeutics
• Replimune

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jpz3rc

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900